VivoSeq
Other

Peripheral Vertigo

7

Pipeline Programs↗

1

Active Trials↗

4

Companies Involved↗

Peripheral Vertigo is an early-stage landscape with 7 programs across 4 companies. The most active players are Tarsa Therapeutics, Inc., Akero Therapeutics, UCB. 3 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

32/100

Pipeline Velocity

0/100

Mech. Concentration

67/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

T

Tarsa Therapeutics, Inc.

1 program

Phase 2Akero Therapeutics logo

Akero Therapeutics

1 program

Phase 3UCB logo

UCB

1 program

ApprovedP

Parkedale

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

4

clinical trials

Completed2 · 50%
Not yet recruiting1 · 25%
Unknown status1 · 25%

Clinical Trials

Trial Activity

Efficacy and Safety of Intravenous Diazepam Given at 2 Different Doses Compared to Placebo in Acute Peripheral Vertigo
Not yet recruiting·UUniversity of Monastir·Phase 3·NCT06293989·1,000 enrolled
Sodium Bicarbonate for Acute Peripheral Vertigo
Unknown status·NNational Taiwan University Hospital·N/A·NCT05676216·225 enrolled
Comparison of Efficacy Between Piracetam and Dimenhydrinate in Patients With Peripheral Vertigo
Completed·KKocaeli University·Phase 4·NCT01890538·94 enrolled
AM-125 in the Treatment of Acute Peripheral Vertigo Following Neurosurgery
Completed·AAuris Medical AG·Phase 2·NCT03908567·124 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)